Minerva Neurosciences, Inc.
NERV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001598646
No open-market purchases or sales by Minerva Neurosciences, Inc. insiders were filed in the last 90 days; 61 institutions reported holding it in 13F filings for Q2 2026, worth $234.8M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Minerva Neurosciences, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 22 | 22 | 0 |
| Shares | 2.09M | 1.95M | −133.8K (−6.4%) |
| Value | $4.63M | $3.31M | −$1.32M (−28.5%) |
New holders (3)
Institutions that held Minerva Neurosciences, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Apella Capital, LLC | 20,625 | $27.6K | 0.00% |
| Farther Finance Advisors, LLC | 100 | $155 | 0.00% |
| FMR LLC | 25 | $43 | 0.00% |
Sold out (3)
Institutions that held Minerva Neurosciences, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| UBS Oconnor LLC | 107,256 | $238.1K |
| Northern Trust Corp | 36,878 | $81.9K |
| TFC Financial Management | 186 | $414 |